Table 2 Multivariable analyses for prognostic indicators of survival outcomes.
Variable | Progression free survival | Overall survival | Cancer Specific Survival | |||
|---|---|---|---|---|---|---|
P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | |
Age at diagnosis (years) | ||||||
≤ 65 versus > 65 | 0.135 | – | 0.119 | – | 0.093 | – |
Surgical technique | ||||||
Open versus laparoscopically | 0.205 | – | 0.277 | – | 0.141 | – |
BMI | ||||||
< 18.5 versus 18.5–24 versus > 24 | 0.048 | 1.066 (1.012–1.098) | 0.223 | – | 0.053 | – |
CVE risk (ANZHEN) | ||||||
Low versus intermediate versus high | 0.532 | – | 0.031 | 1.294 (1.068–1.481) | 0.286 | – |
Tumor size | ||||||
< 2 cm versus ≥ 2 cm | 0.018 | 1.881 (1.562–2.041) | 0.435 | – | 0.022 | 1.561 (1.076–1.858) |
Lymphovacular invasion | ||||||
Positive versus negative | 0.039 | 1.133 (1.008–1.205) | 0.385 | – | 0.407 | – |
Chemotherapy | ||||||
Yes versus No | < 0.001 | 6.327 (5.115–7.793) | 0.013 | 2.336 (1.956–2.883) | 0.008 | 3.073 (2.533–3.738) |
Pathological T stage | ||||||
≤ T2 versus ≥ T3 | < 0.001 | 5.615 (4.823–6.326) | 0.004 | 3.942 (3.254–4.823) | 0.025 | 1.432 (1.153–1.703) |
Lymph node involvement | ||||||
Nx/N0 versus N1 | 0.036 | 1.218 (1.034–1.502) | 0.008 | 3.011 (2.264–3.755) | 0.019 | 1.803 (1.632–1.974) |
Tumor grade | ||||||
G1 versus G2 versus G3 | 0.003 | 4.322 (3.662–4.918) | 0.027 | 1.418 (1.182–1.711) | 0.007 | 3.223 (2.817–3.541) |
Tumor location | ||||||
Renal pelvis versus ureter versus both | 0.638 | – | 0.453 | – | 0.335 | – |
